MedTrace Logo

Change of Glucose Metabolism and Fibrosis Markers in Patients With Hepatitis C Under Treatment With Antiviral Agents

NCT03908294 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 46

Last updated 2020-07-21

No results posted yet for this study

Summary

Chronic hepatitis C infection is associated with changes of glucose metabolism end increased frequency of impaired glucose tolerance. This might be a additional risk factor for disease and fibrosis progression. The study aims to evaluate whether a therapy with direct-acting antiviral agents leading to a sustained virologic response directly impacts parameters reflecting glucose metabolism and fibrosis.

Conditions

  • Glucose Metabolism Disorders
  • Liver Fibrosis
  • Hepatitis C

Interventions

DIAGNOSTIC_TEST

Lab tests, non-invasive fibrosis (Fibroscan/ARFI)

Patient characteristics, lab values reflecting glucose metabolism and non-invasive fibrosis tests are documented at baseline, during therapy and up to one year after end of treatment.

Sponsors & Collaborators

  • Johann Wolfgang Goethe University Hospital

    lead OTHER

Principal Investigators

  • Tania Welzel, MD · Prof.

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-13
Primary Completion
2020-04-01
Completion
2020-04-01

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03908294 on ClinicalTrials.gov